Oncology · Head and Neck CancerTrial Updateclinicalmid-term

Durvalumab and Cetuximab Combination Trial for Head and Neck Cancer

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AstraZeneca87 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 6:32:06 AM

Assessment confidence: 89% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of durvalumab combined with cetuximab is significant as it could enhance AstraZeneca's oncology portfolio and provide a new therapeutic option for patients with recurrent or metastatic head and neck cancer. The trial's outcomes may influence competitive positioning in a challenging treatment landscape. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (23 high-relevance).

Strategic Assessment

Success in this trial may enhance AstraZeneca's portfolio in oncology and provide a new treatment option for a challenging patient population. The strongest clinical anchor is Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov), entity match (astrazeneca); patient population match (metastatic). In Oncology · Head and Neck Cancer, 4 regulatory and 4 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM (Humanexa Signals) — entity match (astrazeneca). Secondary pressure from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer. This trial could position AstraZeneca favorably in the competitive landscape for head and neck cancer treatments, particularly against existing therapies.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval). Positive trial results could facilitate expedited regulatory approval, impacting the timeline for bringing this combination therapy to market.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, this combination therapy could capture market share from existing treatments, potentially leading to increased revenue for AstraZeneca in the oncology sector.
Upside for AstraZeneca may improve if Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Upside for AstraZeneca may improve if Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. (PubMed) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ClinicalTrials.govhigh relevance
Entity match (astrazeneca); Patient population match (metastatic)
FDA document
View source
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (metastatic)
FDA document
View source
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govhigh relevance
Entity match (durvalumab)
FDA document
View source
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (durvalumab)
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

AstraZeneca's Elecoglipron Phase III Trials Target Obesity and T2DM
Humanexa Signalshigh relevance
Entity match (astrazeneca)
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (metastatic)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
durvalumab
cetuximab

Commercial impact

medium

If successful, this combination therapy could capture market share from existing treatments, potentially leading to increased revenue for AstraZeneca in the oncology sector.

Regulatory impact

medium

Positive trial results could facilitate expedited regulatory approval, impacting the timeline for bringing this combination therapy to market.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.